

of Housing and Community Affairs. The one-year contract may be renewed contingent upon availability of funds.

Request for Proposal packets will be available for pick-up or mailing beginning April 13, 2015. The deadline to submit proposals is 5:00 p.m. May 1, 2015. Proposals will be opened following the deadline.

TRD-201500983

Karen Swenson

Executive Director

Greater East Texas Community Action Program

Filed: March 24, 2015



## Texas Health and Human Services Commission

### Public Notice - Disproportionate Share Hospital

The Texas Health and Human Services Commission (HHSC) announces its intent to submit an amendment to the Texas State Plan for Medical Assistance (state plan) under Title XIX of the Social Security Act. The proposed amendment concerns Disproportionate Share Hospital (DSH) reimbursement and is intended to add additional detail to the payment allocation methodology to address potential unique situations pertaining to available funding. The amendment is proposed to be effective May 1, 2015.

#### Impact on aggregate expenditures

The proposed amendment is estimated to result in no change in the amount of federal funds eligible to be received by the state. The proposed amendment may result in additional costs to state government as a result of enforcing or administering the proposed amendment during the first five years the proposed amendment is in effect if additional state funds are identified as a source of non-federal funds for DSH payments. It is not possible to estimate the additional costs to the state, if any, at this time.

Interested parties may obtain copies of the proposed amendment by contacting Pam McDonald, Rate Analysis Department, by mail at the Rate Analysis Department, Texas Health and Human Services Commission, P.O. Box 149030, H-400, Austin, Texas 78714-9030; by telephone at (512) 707-6079; by facsimile at (512) 730-7475; or by e-mail at pam.mcdonald@hhsc.state.tx.us. Copies of the proposal will also be made available for public review at the local offices of the Texas Department of Aging and Disability Services.

TRD-201500971

Karen Ray

Chief Counsel

Texas Health and Human Services Commission

Filed: March 23, 2015



## Department of State Health Services

### Amendment to the Texas Schedules of Controlled Substances

This amendment to the Texas Schedules of Controlled Substances was signed by the Interim Commissioner of the Department of State Health Services, and will take effect 21 days following publication of this notice in the *Texas Register*.

The Administrator of the Drug Enforcement Administration (DEA) issued a final order to remove naloxegol from Schedule II of the Controlled Substances Act (CSA), effective January 23, 2015. This final order was published in the Federal Register, Volume 80, Number 15, pages 3468-3470. The Administrator of the DEA finds that upon consideration of its own eight-factor analysis and relevant data, naloxegol

does not meet the requirements for inclusion in any schedule and will be removed from control under the CSA.

The Administrator of the Drug Enforcement Administration (DEA) issued a final order temporarily placing N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide ("AB-CHMINACA"); N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide ("AB-PINACA"); and [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone ("THJ-2201") into Schedule I of the CSA effective January 30, 2015. This final order was published in the Federal Register, Volume 80, Number 20, pages 5042-5047. The Administrator has taken action based on the following.

1. AB-CHMINACA, AB-PINACA and THJ-2001 have no currently accepted medical use in treatment in the United States;
2. There is lack of accepted safety for use of under medical supervision;
3. AB-CHMINACA, AB-PINACA and THJ-2001 have a high potential for abuse; and
4. Temporarily placing AB-CHMINACA, AB-PINACA and THJ-2001 into Schedule I is necessary to avoid an imminent hazard to the public safety.

Pursuant to §481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced actions were published in the Federal Register; and, in the capacity as Interim Commissioner of the Department of State Health Services, Kirk Cole does hereby order that the substances N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide ("AB-CHMINACA"); N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide ("AB-PINACA"); and [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone ("THJ-2201") be placed into Schedule I temporarily scheduled substances; and naloxegol be removed from Schedule II.

#### SCHEDULE I

Schedule I consists of:

-Schedule I opiates

\*\*\*

-Schedule I opium derivatives

\*\*\*

-Schedule I hallucinogenic substances

\*\*\*

-Schedule I stimulants

\*\*\*

-Schedule I depressants

\*\*\*

-Schedule I Cannabimimetic agents

\*\*\*

-Schedule I temporarily listed substances subject to emergency scheduling by the United States Drug Enforcement Administration.

Unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following substances or that contains any of the substance's salts,

isomers, and salts of isomers if the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation.

1. (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (Other names: UR-144 and 1-pentyl-3-(2,2,3,3-tetramethylcyclopropyl)indole);
2. [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (Other names: 5-fluoro-UR-144 and 5-F-UR-144 and XLR11 and 1-(5-fluoro-pentyl)-3-(2,2,3,3-tetramethylcyclopropyl)indole);
3. N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (Other names: APINACA, AKB48);
4. 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
5. 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
6. 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
7. Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: PB-22; QUPIC);
8. Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 5-fluoro-PB-22; 5F-PB-22);
9. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: AB-FUBINACA);
10. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: ADB-PINACA);
11. 4-methyl-N-ethylcathinone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)propan-1-one);
12. 4-methyl-alpha-pyrrolidinopropiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-MePPP; MePPP; 4-methyl-[alpha]-pyrrolidinopropiophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)propan-1-one);
13. alpha-pyrrolidinopentiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: [alpha]-PVP; [alpha]-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one);
14. Butylone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one);
15. Pentadone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: [alpha]-methylaminovalerophenone; 2-(methylamino)-1-phenylpentan-1-one);
16. Pentylone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one);
17. 4-fluoro-N-methylcathinone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-FMC; flephedrone; 1-(4-fluorophenyl)-2-(methylamino)propan-1-one);

18. 3-fluoro-N-methylcathinone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 3-FMC; 1-(3-fluorophenyl)-2-(methylamino)propan-1-one);

19. Naphyrone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one);

20. alpha-pyrrolidinobutiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: [alpha]-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one);

\*21. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (Other names: "AB-CHMINACA");

\*22. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (Other names: "AB-PINACA"); and

\*23. [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (Other names: "THJ-2201").

## SCHEDULE II

Schedule II consists of:

-Schedule II substances, vegetable origin or chemical synthesis

The following substances, however produced, except those narcotic drugs listed in other schedules:

(1) Opium and opiate, and a salt, compound, derivative, or preparation of opium or opiate, other than thebaine-derived butorphanol, \*naloxegol naloxone, and its salts, naltrexone and its salts, and nalmeferone and its salts, but including:

- (1-1) Codeine;
- (1-2) Dihydroetorphine;
- (1-3) Ethylmorphine;
- (1-4) Etorphine hydrochloride;
- (1-5) Granulated opium;
- (1-6) Hydrocodone;
- (1-7) Hydromorphone;
- (1-8) Metopon;
- (1-9) Morphine;
- (1-10) Opium extracts;
- (1-11) Opium fluid extracts;
- (1-12) Oripavine;
- (1-13) Oxycodone;
- (1-14) Oxymorphone;
- (1-15) Powdered opium;
- (1-16) Raw opium;
- (1-17) Thebaine; and
- (1-18) Tincture of opium.

(2) A salt, compound, isomer, derivative, or preparation of a substance that is chemically equivalent or identical to a substance described by Paragraph (1) of Schedule II substances, vegetable origin or chemical synthesis, other than the isoquinoline alkaloids of opium;

(3) Opium poppy and poppy straw;

(4) Cocaine, including:

(4-1) its salts, its optical, position, and geometric isomers, and the salts of those isomers; and

(4-2) coca leaves and a salt, compound, derivative, or preparation of coca leaves that is chemically equivalent or identical to a substance described by this paragraph, other than decocainized coca leaves or extractions of coca leaves that do not contain cocaine or ecgonine; and

(5) Concentrate of poppy straw, meaning the crude extract of poppy straw in liquid, solid, or powder form that contains the phenanthrene alkaloids of the opium poppy.

-Opiates

\*\*\*

-Schedule II stimulants

\*\*\*

-Schedule II depressants

\*\*\*

-Schedule II hallucinogenic substances

\*\*\*

-Schedule II precursors

\*\*\*

Changes to the schedules are designated by an asterisk (\*).

TRD-201501014

Lisa Hernandez

General Counsel

Department of State Health Services

Filed: March 25, 2015



## Texas Higher Education Coordinating Board

Request for Proposals - Financial Advisory Services

RFP Number **781-6-14429**

The Texas Higher Education Coordinating Board (THECB) is seeking proposals from qualified respondents to establish a contract for Financial Advisory Services, in accordance with the requirements contained in this Request for Proposals (RFP).

Bonds issued by the THECB are private activity bonds. It is anticipated that any such bonds will be tax-exempt, but subject to the Alternative Minimum Tax (AMT). The decision to use a negotiated or competitive sale will be determined by the Board based on prevailing market conditions.

### Statement of Work:

The financial advisor shall be responsible for all duties and services necessary to facilitate the issuance of bonds and other debt obligations by the Board. Such duties and services shall include, but are not limited to:

- (1) Devising and recommending a plan of financing for all bonds or other debt instruments to be issued by the Board, with terms and conditions that will result in the most advantageous terms for the Board.
- (2) Assisting Board staff in determining the timing and the sizing of each bond issue.
- (3) Assisting Board staff with the evaluation of proposals for underwriting services.

(4) Assisting bond counsel in the preparation of bond offering documents including resolutions, preliminary official statements, final official statements, and other bond-related documents.

(5) Preparing financial information for rating agencies and assisting with presentations to such agencies.

(6) Providing advice in regard to the need for credit enhancement and liquidity facilities, and assisting in the negotiations with providers of such services.

(7) Assisting the Board in presentations to credit enhancers, or prospective bond purchasers.

(8) Monitoring and assisting in the negotiation of all fees and expenses incurred in connection with the issuance of the bonds, including those proposed by the Board's underwriters.

(9) Reviewing all documents that are customary and necessary in order to structure and issue bonds, and attending all document meetings and/or conference calls.

(10) Soliciting bids for printing bond offering documents, ratings, and other related services when necessary.

(11) Assisting in closing details and post-closing duties, including the development of closing memorandum and preparation of the Bond Review Board final report with final costs of issuance.

(12) Assisting in making presentations, required submissions, and obtaining approval of the Bond Review Board, the Legislative Budget Board, and any other State entity with supervisory powers over the issuance of bonds by the Board.

(13) Attending meetings of the Board, Bond Review Board, legislative committees, or other meetings to the extent required and/or requested.

(14) Providing advice on continuing disclosure requirements in relation to the bonds. Reviewing continuing disclosure annual reports required by Rule 15c2-12 of the Securities and Exchange Commission (SEC).

(15) After bond issuance, interpreting bond provisions and covenants when requested by the Board and/or staff.

(16) Advising staff of new developments in the municipal bond industry.

(17) Monitoring and advising Board staff on refunding opportunities, cash redemptions, debt defeasance, and other financial products that would help lower the Board's cost of borrowing money.

(18) Providing financial advisory support for all other matters necessary or incidental to the issuance of the bonds or administering the Board's loan programs. This requires the Financial Advisor to have the necessary software to prepare cash flow modeling and forecasting of the Board's student loan portfolio.

(19) Providing information on questions and issues posed by Board and Board staff on an ongoing basis.

RFP documentation may be obtained by contacting:

Texas Higher Education Coordinating Board

P.O. Box 12788

Austin, Texas 78711-2788

(512) 427-6142

theresa.lopez@theeb.state.tx.us

RFP documentation is also located on the THECB's website at:

[www.theeb.state.tx.us/Agency Info](http://www.theeb.state.tx.us/Agency Info)